

Catalog	Unit
TBS10350-0.5MG	0.5 mg
TBS10350-1MG	1 mg
TBS10350-5MG	5 mg

Description

InVivoMAb Anti-Human CD319 (SLAMF7) Antibody is a monoclonal antibody that specifically binds to human CD319, a cell surface receptor expressed on natural killer (NK) cells, plasma cells, and subsets of T cells. CD319 plays a key role in immune cell activation, adhesion, and cytotoxicity. This antibody is widely used in research to investigate immune cell signaling, antibody-dependent cellular cytotoxicity (ADCC), and potential therapeutic interventions in autoimmune diseases and cancer.

Synonyms

Anti-SLAMF7 antibody, Anti-CS1 antibody, Anti-CRACC antibody, Anti-CD2L antibody.

Product Details

- Applications:** ELISA, Neutralization, WB
- Species reactivity:** Human
- Host:** Human
- Isotype:** IgG1, kappa
- Target:** SLAMF7, CRACC, Protein 19A, SLAM family member 7, CD2-like receptor-activating cytotoxic cells, Membrane protein FOAP-12, CD319, Novel Ly9, CD2 subset 1, CS1.
- Uniprot:** Q9NQ25
- Concentration:** 3 mg/ml
- Purity:** >95%
- Formulation:** Liquid
- Storage buffer:** 0.01M PBS, pH 7.4.
- Purification:** Protein A/G purified from cell culture supernatant.
- Clonality:** Monoclonal
- Storage:** Store -20°C up to 12 months, and -80°C for long term. Avoid repeated freeze-thaw cycles.

Data Image




Fig. 1. SDS-PAGE for InVivoMAb Anti-Human CD319/SLAMF7 Antibody.

MW: Molecular Weight (kDa) Marker.
 R: Reducing conditions.
 NR: Non-Reducing conditions.

For research use only.